Drug Research

QIAGEN and Neuron23TM Inc., an early-stage biotechnology company focused on creating precision medications for genetically defined neurological and immunological illnesses, have announced a partnership to create a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease. According to the terms...

Australia has authorised the use of a new targeted therapy for the treatment of cholangiocarcinoma, a rare bile duct cancer. The Therapeutic Goods Administration (TGA) has granted PEMAZYRE (pemigatinib) provisional approval for the treatment of adult patients with metastatic...

Beyfortus has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency to treat lower respiratory tract sickness caused by the respiratory syncytial virus (RSV) in neonates and young children. If authorised, Beyfortus,...

Brussels marks the beginning of the European canSERV initiative, which aims to defragment the European cancer research landscape. CanSERV will give academia and business exposure to cross-cutting services and assistance from fundamental science up to clinical application over the...

The World Health Organization (WHO) has discontinued the use of two COVID-19 antibody treatments on the grounds that Omicron and the variant's most recent offspring have probably made them ineffective. The two treatments were among the first drugs created in...

Despite the increased prevalence of both communicable and non-communicable diseases in the nation, the commercial potential for medication manufacturers in Cambodia will remain restricted, according to a report by Fitch Solutions. Based on the report, Cambodia's healthcare system is still...

Upcoming gene therapies may be the most economical option for people with haemophilia types A and B to address their illness, even with a steep price tag of $2.5 million for each treatment. In a preliminary evidence report made...